Interferon free hepatitis C treatment regimens: The beginning of another era

Fred Poordad; Grace M. Chee

doi:10.1007/s11894-011-0229-1

Interferon free hepatitis C treatment regimens: The beginning of another era

Fred Poordad, Grace M. Chee

Producción científica: Article › revisión exhaustiva

8 Citas (Scopus)

Resumen

Hepatitis C is a virus affecting millions worldwide and is a major health risk. With the potentially severe adverse event profile of the current backbone of therapy, interferon, there is an impetus to discover interferon free treatment regimens. With the development of new oral direct acting antivirals, interferon free regimens may be available in the next few years. This article discusses some of the preliminary data from interferon free studies.

Idioma original	English (US)
Páginas (desde-hasta)	74-77
Número de páginas	4
Publicación	Current Gastroenterology Reports
Volumen	14
N.º	1
DOI	https://doi.org/10.1007/s11894-011-0229-1
Estado	Published - feb 2012
Publicado de forma externa	Sí

ASJC Scopus subject areas

Gastroenterology

Acceder al documento

10.1007/s11894-011-0229-1

Otros archivos y enlaces

Citar esto

@article{5ae9a8e3c44348748d239818b4177b78,

title = "Interferon free hepatitis C treatment regimens: The beginning of another era",

abstract = "Hepatitis C is a virus affecting millions worldwide and is a major health risk. With the potentially severe adverse event profile of the current backbone of therapy, interferon, there is an impetus to discover interferon free treatment regimens. With the development of new oral direct acting antivirals, interferon free regimens may be available in the next few years. This article discusses some of the preliminary data from interferon free studies.",

keywords = "Direct acting antivirals, Hepatitis C, Interferon, Interferon free, Polymerase inhibitor, Protease inhibitor, Ribavirin, SVR",

author = "Fred Poordad and Chee, {Grace M.}",

note = "Funding Information: Disclosure F. Poordad has received consultant fees and grant funding from Merck, Vertex, Gilead, Pharmassett, Anadys, Achillion, BMS, Abbott and Genentech, and has received payment for development of educational presentations from Vertex, Merck, Genentech, and Gilead; G. Chee reported no potential conflicts of interest relevant to this article.",

year = "2012",

month = feb,

doi = "10.1007/s11894-011-0229-1",

language = "English (US)",

volume = "14",

pages = "74--77",

journal = "Current Gastroenterology Reports",

issn = "1522-8037",

publisher = "Current Medicine Group",

number = "1",

}

TY - JOUR

T1 - Interferon free hepatitis C treatment regimens

T2 - The beginning of another era

AU - Poordad, Fred

AU - Chee, Grace M.

N1 - Funding Information: Disclosure F. Poordad has received consultant fees and grant funding from Merck, Vertex, Gilead, Pharmassett, Anadys, Achillion, BMS, Abbott and Genentech, and has received payment for development of educational presentations from Vertex, Merck, Genentech, and Gilead; G. Chee reported no potential conflicts of interest relevant to this article.

PY - 2012/2

Y1 - 2012/2

N2 - Hepatitis C is a virus affecting millions worldwide and is a major health risk. With the potentially severe adverse event profile of the current backbone of therapy, interferon, there is an impetus to discover interferon free treatment regimens. With the development of new oral direct acting antivirals, interferon free regimens may be available in the next few years. This article discusses some of the preliminary data from interferon free studies.

AB - Hepatitis C is a virus affecting millions worldwide and is a major health risk. With the potentially severe adverse event profile of the current backbone of therapy, interferon, there is an impetus to discover interferon free treatment regimens. With the development of new oral direct acting antivirals, interferon free regimens may be available in the next few years. This article discusses some of the preliminary data from interferon free studies.

KW - Direct acting antivirals

KW - Hepatitis C

KW - Interferon

KW - Interferon free

KW - Polymerase inhibitor

KW - Protease inhibitor

KW - Ribavirin

KW - SVR

UR - http://www.scopus.com/inward/record.url?scp=84857536087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857536087&partnerID=8YFLogxK

U2 - 10.1007/s11894-011-0229-1

DO - 10.1007/s11894-011-0229-1

M3 - Article

C2 - 22105465

AN - SCOPUS:84857536087

SN - 1522-8037

VL - 14

SP - 74

EP - 77

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

IS - 1

ER -

Interferon free hepatitis C treatment regimens: The beginning of another era

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto